卵巢癌中的免疫逃避:对免疫疗法和新兴治疗方法的含义
Romi Gupta1, Raj Kumar2, Courtney A Penn3
1Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35233, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, AL 35233, USA.
本综述探讨了卵巢癌 (OC) 中的免疫逃避,并讨论了免疫疗法,包括新兴治疗方法,如何改善患者的治疗结果. 了解这些机制是推动卵巢癌治疗的关键.
科学领域:
- 妇科瘤学 妇科瘤学
- 免疫学 免疫学 免疫学
- 癌症遗传学 癌症遗传学
背景情况:
- 卵巢癌 (OC) 是一种具有不同亚型的致命妇科恶性瘤.
- 目前的治疗方法包括化疗,PARP抑制剂,贝瓦齐祖马布,荷尔蒙疗法,免疫疗法和ADC.
- 免疫逃避是OC进展和治疗耐药性的关键因素.
研究的目的:
- 审查OC中的免疫逃避机制.
- 讨论遗传学,瘤微环境和异质性在免疫逃避中的作用.
- 评估OC目前和新兴免疫疗法的临床结果.
主要方法:
- 对OC免疫学和免疫治疗的临床前和临床研究的文献综述.
- 对影响免疫逃避的遗传,微环境和异质性因素的分析.
- 综合有关免疫治疗策略及其临床疗效的数据.
主要成果:
- 卵巢癌表现出复杂的免疫逃避策略,受宿主遗传和瘤特征的影响.
- 免疫疗法是有前途的,但临床结果因治疗组合和患者选择而异.
- 新兴的免疫疗法在克服治疗耐药性方面显示出显著的潜力.
结论:
- 针对免疫逃避机制对于有效的卵巢癌治疗至关重要.
- 组合免疫疗法和新药为患者提供了新的希望.
- 对个性化免疫治疗方法的进一步研究是有必要的,以获得最佳的患者益处.
更多相关视频
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
05:42Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
